# clm_DB412511FD99

subject: Eli Lilly and Company (/record/eli-lilly.md)  
predicate: quarterly_research_and_development  
value: 1,802,900,000 United States dollar  
valid_from: 2022-09-30  
valid_to: 2023-03-31  
published: 2022-11-01  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_28ED890F5BBC  
last_updated: 2026-11-08  
cite: AsOf. "Eli Lilly and Company quarterly research and development: 1,802,900,000 United States dollar", as of 2022-09-30 (until 2023-03-31). Claim clm_DB412511FD99, https://asof.is/claim/clm_DB412511FD99, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2022, filed 2022-11-01  

## Sources

- https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm (primary, SEC EDGAR 10-Q Q3 FY2022, published 2022-11-01)

## Supersedes

- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_research_and_development | 1,781,900,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_DB412511FD99](/claim/clm_DB412511FD99.md) | [clm_7E87516D4A1A](/claim/clm_7E87516D4A1A.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.